Alemtuzumab 8y outcomes (ECTRIMS 2018)

  UK NHS England MS Treatment algorithm

If you don't know where you are going, all roads lead there; and in this case to alemtuzumab! 

But can alemtuzumab puts its money where it's mouth is? 

In ECTRIMS we saw the publication of one their original clinical trial (CARE-MS II) follow up results after an 8 year period (see poster below).
I'll leave you to come to your own conclusions on these findings, but alemtuzumab is here to stay.

Labels: ,